Skip to main content

Table 3 Crude and adjusted hazard ratios for the association between variable and the risk for 5-year mortality among 2565 enrolled subjects including SLE and matched non-SLE control subjects

From: Impact of systemic lupus erythematosus on the 5-year survival of critically ill septic patients

  Univariable Model-1 Model-2 Model-3 Model-4
Crude Hrs Adjusted Hrs Adjusted Hrs Adjusted Hrs Adjusted Hrs
SLE (non-SLE as reference) 2.27 (2.01–2.57) 2.20 (1.94–2.49) 2.21 (1.95–2.50) 2.01 (1.77–2.27) 1.47 (1.22–1.77)
Age, (per 1 year increment) 1.03 (1.02–1.03) 1.03 (1.02–1.03) 1.03 (1.02–1.03) 1.02 (1.01–1.02) 1.02 (1.02–1.02)
Gender (male) 1.38 (1.19–1.61) 1.24 (1.07–1.45) 1.23 (1.06–1.44) 1.14 (0.98–1.33) 1.11 (0.95–1.30)
Urbanisation levels
 Urban Ref.   Ref. Ref. Ref.
 Suburban 1.01 (0.88–1.17)   1.06 (0.92–1.22) 1.09 (0.94–1.25) 1.11 (0.96–1.28)
 Rural 0.97 (0.83–1.14)   0.89 (0.76–1.05) 0.92 (0.78–1.07) 0.94 (0.80–1.11)
Low insured incomea 1.01 (0.90–1.13)   1.09 (0.97–1.22) 1.06 (0.95–1.19) 1.08 (0.97–1.21)
CCI > 3 (0-3 as reference) 3.06 (2.72–3.43)    2.27 (2.01–2.57) 2.23 (1.97–2.53)
Recent hospitalised infectionb 2.04 (1.75–2.38)    1.35 (1.13–1.60) 1.33 (1.12–1.59)
Medications
Glucocorticoid dosage groupc
 0 mg/day Ref.     Ref.
 0-5 mg/day 1.62 (1.31–2.00)     1.18 (0.95–1.46)
 ≥ 5 mg/day 2.63 (2.17–3.18)     1.55 (1.27–1.90)
DMARD
 Methotrexate 2.55 (1.91–3.39)     2.19 (1.61–2.99)
 Sulfasalazine 1.68 (1.03–2.75)     0.84 (0.50–1.42)
 Hydroxychloroquine 2.04 (1.78–2.35)     0.98 (0.80–1.19)
 Immunosuppressantsd 2.14 (1.87–2.45)     1.45 (1.22–1.74)
  1. aInsured income lower than median income (21,900 New Taiwan dollars). bWithin 3 months prior to index admission. cPrednisolone equivalent. dCyclophosphamide, azathioprine, cyclosporine, mycophenolate, and mycophenolic. Abbreviations: SLE Systemic lupus erythematosus, CCI Charlson comorbidity index, DMARD Disease-modifying antirheumatic drug